CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call - Final Transcript

Aug 06, 2020 • 05:30 pm ET

Previous

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Analyst
Mohit Bansal

starting some more trials, and probably the enrollment will speed up now?

Executive
Carlos Campoy

Yes. That makes sense. You noticed it's -- we had a significant number of expenses that happened in Q1 that are one-time, particularly, around licensing fees that were associated with the milestones that we received in Q1. So, Q1 was the aberration not Q2, and you should see it continue at a lower level than what you saw in Q1, but we haven't really guided for the full-year R&D expense line.

Analyst
Mohit Bansal

Very helpful. Thank you very much.

Operator
Operator

Thank you. Our next question comes from Joe Catanzaro of Piper Sandler. Your line is open.

Analyst
Joe Catanzaro

Hey, guys. Thanks so much for taking my question here. Maybe just one quick one, just wondering, if you have any thoughts or whether the recent EpCAM for the BCMA, ADC and ocular tox discussion provides any insight or future plans around CX-2009 whether it's collecting the data. Or just how the FDA thinks about that toxicity in the context of an advanced cancer population?

Executive
Sean A. McCarthy

Yes. Hi, Joe. Great question. Certainly something that we're looking at and at the time being we have and continue to remain confident that we can manage ocular toxicities with the regimens that have been used previously with DM4 conjugates. But we're certainly going to learn everything we can from those discussions and make any additional modifications or improvements that we may be able to make, but work-in-progress.

Analyst
Joe Catanzaro

Okay, that's it from me. Thanks for taking my question.

Executive
Sean A. McCarthy

You're welcome. Thanks.

Operator
Operator

Thank you. I'm showing no questions at this time. I'd like to turn the call back to Dr. McCarthy for any closing remarks.

Executive
Sean A. McCarthy

Great, thank you very much. Once again, I'd like to thank everyone for listening in today, we had another very strong quarter. And as I said, despite the many challenges presented to all of us by the COVID-19 situation very proud of the team and proud of our progress as we move the pipeline and platform forward. So, I hope everybody stays well, stay safe and we look forward to talking to you all again soon.

Operator
Operator

[Operator Closing Remarks]